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26 Abstract
27
28 We propose to analyse the long-term follow-up in patients older than 65 years of age who received a mechanical valve in the aortic
29 position, using death and prosthetic-related complications as endpoints. From April 1988 to December 1995, 144 consecutive patients 65–
30 75 years of age (mean 67.7"2.5) were enrolled. Total duration of follow-up was 1663 patient-years (median 13.0 years) and was complete
31 for 99% of the patients. Thirty-day mortality was 1.4% (ns2). At the end of the study, 77 patients (53.8%) were alive, with ages ranging
32 from 77 to 91 years (mean 82.1"3.2 years). The overall 5-, 10- and 15-year actuarial survival was 87.4%"3.0, 67.7%"4.3 and 58.5%"4.5,
33 respectively. Freedom from stroke was 93.3"3.1%, 84.6"3.3% and 71.7"4.5%, respectively, after identical periods. Freedom from major
34 bleeding was 97.2"1.1%, 90.4"3.5% and 86.4"4.0%, respectively. Freedom from endocarditis was 95.7"2.3%, 95.0"2.1% and 94.4"2.5%,
35 respectively, and freedom from reoperation was 98.0"1.2%, 97.6"1.3%, 96.9"2.4% and 96.4"2.6%, respectively. Freedom from major
36 valve-related events was 87.7"2.6%, 73.9"3.4% and 61.5"4.6%, respectively. Nearly two-thirds of the patients were alive and free from
37 major adverse valve-related events. Hence, we consider implantation of a mechanical prosthesis in elderly patients safe and appropriate,
38 but the choice must be tailored for each specific patient.
39  2009 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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43
45 1. Introduction
46 There is no perfect valve substitute. All prostheses,
47 whether mechanical or biological, involve some compro-
48 mise and all introduce a new disease process, the prosthetic
49 disease. Considerations for choosing between a mechanical
50 valve and a bioprosthesis concern haemodynamic perform-
51 ance, long-term durability and the need for chronic
52 anticoagulation.
53 Currently in Europe and in the USA, there are trends
54 towards increasing the use of tissue valves, in progressively
55 younger patients w1–3x, probably supported by reports of
56 very low rates of bioprosthetic failure in elderly patients 57
w4, 5x, particularly with the newer models w6x.
58 Although there are several studies addressing the behav-
59 iour of mechanical valves in the elderly patients, only a
60 few have long follow-up analysis concerning survival and
61 valve-related events w7–10x. In the present study, we ana-
62 lyse early and late survival, adverse valve-related events
63 and the quality of life in this specific patient population
64 (65–75 years), in a follow-up of up to 20 years.
462
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2. Material and methods
662.1. Patient population
67From April 1988 to December 1995, a total of 144 consec-
68utive patients aged 65–75 years (mean 67.7"2.5 years),
6993 female (64.6%), underwent aortic valve replacement
70(AVR) with a mechanical prosthesis. Patients receiving
71concomitant coronary artery bypass surgery (CABG) and
72other surgical procedures were included. The time interval
73for inclusion in this study was determined to permit at
74least a 12-year period of follow-up.
75During the same time interval, we also implanted 102
76bioprostheses in patients of this age group. The initial
77design of the work was a comparative study between the
78two types of valves, but patients in the biological valve
79group were significantly older, with more co-morbidities,
80which precluded an accurate comparison.
81Preoperatively, 87 patients (60.4%) were in NYHA (New
82York Heart Association) class III or IV, 28 (19.4%) had left
83ventricular dysfunction (ejection fraction -45%) and 30
84(20.8%) were in chronic atrial fibrillation. Table 1 summa-
85rizes the baseline demographic and clinical characteristics
86of the patients.
87Surgical indications for AVR were: stenosis (ns101,
8870.1%), insufficiency (ns40, 27.8%) and endocarditis (ns3,
892.1%), including one case of aortic prosthetic endocarditis.
90Five cases were re-operative cardiac interventions (3.5%).
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Table 1
4 Characteristics of the study population
5
DemographicalyClinical n (%) or mean"S.D.
6
11 Age (years, mean) 67.7"2.5
12 Sex (female) 51 (35.4%)
13 Body surface area (m )2 1.72"0.74
14 NYHA class III–IV 87 (60.4%)
15 LV dysfunction (EF-45%) 28 (19.4%)
16 Valve pathology (predominant lesion)
17 Insufficiency 40 (27.8%)
18 Stenosis 101 (71%)
19 Endocarditis 3 (2.1%)
20 Chronic atrial fibrillation 30 (20.8%)
21 Previous cardiac surgery 5 (3.5%)
22
23
Surgery24
ECC time (min) 84.4"12.725
Aortic cross-clamping (min) 54.8"12.726
Aortic cross-clamping time (min) 54.8"12.72728
Associated procedures29
CABG 16 (11.1%)30
Mitral valve repair 14 (9.7%)31
Reduction ascending aortoplasty 3 (2.1%)32
Mitral valve replacement 3 (2.1%)33
Mitral and tricuspid valve repair 2 (1.4%)34
Ascending aorta replacement 1 (0.7%)
35
36 NYHA, New York Heart Association; EF, ejection fraction; ECC, extracor-
37 poreal circulation; CABG, coronary artery bypass grafting.
91
The decision to implant a mechanical valve was made
92 jointly by the cardiac surgeon, cardiologist, nurse and
93 patient. Performance status, physical condition, ability to
94 manage anticoagulation (including good family support)
95 and patient’s tolerance to the eventual need for repeat
96 valve replacement were our main determinants of valve
97 selection.
98 2.2. Operative technique and data
99 The operative technique was standardized for all patients
100 and included cardiopulmonary bypass with moderate hypo-
101 thermia (28–308), topical cooling with ice slush in the
102 pericardium and intermittent antegrade cold crystalloid
103 cardioplegia, either in the aortic root or directly in the
104 coronary ostia.
105 Only two types of aortic prostheses were implanted,
106 Medtronic-Hall (Medtronic Inc, Minneapolis, MN, USA) and
107 Carbomedics (Sulzer Medica, Austin, TX, USA), both consid-
108 ered to have low thrombogenicity w11x.
109 Concomitant procedures were performed in 39 patients
110 (27%), the most frequent being CABG and mitral valve
111 repair (Table 1).
112 2.3. Anticoagulant management
113 Anticoagulation was initiated with warfarin on the first or
114 second postoperative day, depending on the patient’s con-
115 dition. During the initial years of this experience, the
116 prothrombin time or index were used to monitor the level
117 of anticoagulation, with a target prothrombin time ratio of
118 1.5–2. More recently, the international normalized ratio
119 (INR) has been used to monitor the level of anticoagulation
120 with a target of 2.0–3.0 units. Control of the prothrombin
121 time or the INR after discharge from the hospital was done
122 by the patient’s physician, after initial stabilization by the
123
surgeons (all patients had a blood sample drawn for anti-
124coagulation control at the time of the last postoperative
125visit, usually at 1 month).
1262.4. Data collection, follow-up and outcome events
127Perioperative data were obtained by review of the
128patient’s hospital records, catheterization reports, cinean-
129giograms and echocardiography. Follow-up information was
130collected during a 3-month period (cross-sectional mode),
131closing end of January 2008. This was done through a
132mailed questionnaire or by telephone interview with sur-
133viving patients, family members or the patient’s physician.
134Follow-up data included information about activity level,
135current symptoms, occurrence of late cardiac and non-
136cardiac events, regularity of anticoagulation control and if
137the INR value was in the target range.
138The total duration of follow-up for the entire cohort was
1391663 patient-years (range 0–19.1 years, median 13.0 years
140(interquartile range 9.1–14.6 years) and was complete for
14199% of the patients (one patient lost for follow-up).
142Prosthetic-related complications were recorded according
143to the 2008 Guidelines for Reporting Mortality and Morbidity
144after Cardiac Valve Interventions w12x. Major adverse valve-
145related events (MAVE) included: valve-related mortality
146(sudden, unexplained death included); all valve-related
147morbidity and need for new permanent pacemaker or
148defibrillator within 14 days after the valve intervention.
1492.5. Statistical analysis
150Data were presented as frequency distributions and simple
151percentages. Continuous variables were expressed as mean"
152standard deviation (S.D.). Patient survival was calculated
153by actuarial analysis according to the Kaplan–Meier meth-
154od, using time zero as the date of operation and late death
155as the end point (with variability expressed as standard
156error of mean). Linearised rates of occurrence for selected
157events were calculated and expressed as % per patient-
158year (pt-yr). Data were analysed using the SPSS software
159package (SPSS, Inc, Chicago, Illinois, USA).
1603. Results
1613.1. Hospital mortality and morbidity
162There was only one hospital death (0.7%), due to aortic
163rupture in the first postoperative day. The patient was
164reopened in extremis in the ICU, but it was not possible to
165control the bleeding. One patient died from sudden death
166two weeks after discharge (30-day mortality, 1.4%).
167One-third of the patients (33.3%), experienced some type
168of postoperative morbidity, the most frequent being rhythm
169disturbances (atrial fibrillationyflutter, complete AV block),
170followed by acute renal failure (creatinine )2 mgydl) and
171respiratory complications (infectious, pneumothorax, pleu-
172ral effusion) (Table 2). Most episodes were minor and easily
173controlled.
174The mean length of hospital stay was 9"2.1 days.
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Table 2
43 Causes of hospital morbidity
44
Complication n (%)
45
50 Rhythm disturbances 23 (16.0)
51 Atrial fibrillationyflutter 20 (13.9)
52 Complete AV block 3 (2.1)
53 Acute renal failure 7 (4.9)
54 Respiratory complications 5 (3.5)
55 Reoperation (bleedingytamponade) 5 (3.5)
56 CVAyTIA 3 (2.1)
57 Others 5 (3.5)
58
59 CVA, cerebro-vascular accident; TIA, transient ischemic attack.
64
Table 3
65 Causes of late death
66
Causes of death n (%)
67
72 Cardiac mortality (non-valve related) 31 (46.9)
73 Heart failure 12 (18.12)
74 Acute myocardial infarction 3 (4.5)
75 Arrhythmias 2 (3.0)
76 Valve-related mortality 14 (21.2)
77 CVA 7 (10.6)
78 Prosthetic endocarditis 3 (4.5)
79 Sudden or unexplained death 3 (4.5)
80 Bleeding event 1 (1.5)
81 Non-cardiac mortality 30 (45.5)
82 Malignancy 10 (15.1)
83 Pulmonary causes 8 (12.1)
84 Head trauma 4 (6.0)
85 Car accident 3 (4.5)
86 Sepsis 2 (3.0)
87 Others 3 (4.5)
88 Unknown 5 (7.6)
89
90 CVA, cerebro-vascular accident.
94
95Fig. 1. Kaplan–Meier survival curve.
175
3.2. Late mortality
176 During the course of this 20-year study, 66 patients died
177 (45.8%). Nearly half of the deaths were non-cardiac, malig-
178 nancies representing a major cause. There were 31 cardiac
179 deaths (46.9%) and only 14 of those were valve-related
180 (21.2%). Stroke was the most frequent cause of valve-
181 related mortality, followed by prosthetic endocarditis
182 and sudden death. The causes of late death are listed in
183 Table 3.
184 At the completion of this study, 77 patients (53.8%) were
185 alive, with ages ranging from 77 to 91 years (mean 82.1"
186 3.2 years).
187 Fig. 1 displays the long-term actuarial survival of the
188 patients. The overall 1-, 5-, 10- and 15-year actuarial sur-
189 vival was 95.1%"2.1, 87.4%"3.0, 67.7%"4.3 and 58.5%"
190 4.5, respectively. When the study population was subdivid-
191 ed in subgroups by age (65–69 years vs. 70–75 years), or
192 according to associated procedures performed, there were
193 no statistical differences regarding overall survival.
194 3.3. Valve-related events
195 3.3.1. Thromboembolism and major bleeding
196 Twenty-six patients (18.0%) experienced a neurological
197 event (CVAyTIA), which was fatal in seven. Five patients
198 who survived a stroke episode remained with some degree
199 of disability, the others recovered fully. Two patients had
200
more than one episode of thromboembolism. One-, 5-, 10-
201and 15-year freedom from stroke (Fig. 2) was 96.1"2.2%,
20293.3"3.1%, 84.6"3.3% and 71.7"4.5%, respectively. The
203linearised incidence was 1.56%ypt-yr.
204Fourteen patients (9.7%) suffered a major haemorrhage
205and one patient died from a spontaneous acute subdural
206haematoma. One-, 5-, 10- and 15-year freedom from major
207bleeding was 99.1"1.2%, 97.2"1.1%, 90.4"3.5% and
20886.4"4.0%, respectively (Fig. 2). The rate of occurrence
209was 0.84%ypt-yr.
210The linearised incidence of the composite outcome throm-
211boembolism plus major bleeding was 2.4%ypt-yr.
2123.3.2. Endocarditis and reoperation
213Eight patients (5.5%) had prosthetic endocarditis, three
214underwent surgery and the remaining were treated medi-
215cally. Three patients died from the event.
216Five patients (3.5%) were subjected to at least one
217reintervention, three because of prosthetic endocarditis,
218one for paravalvular leak and one for nonstructural dys-
219function (entrapment by pannus). Two patients had more
220than one reoperation (endocarditis).
221One-, 5-, 10- and 15-year freedom from endocarditis was
22296.4"1.6%, 95.7"2.3%, 95.0"2.1% and 94.4"2.5%,
223respectively (Fig. 3a), and freedom from reoperation was
22498.0"1.2%, 97.6"1.3%, 96.9"2.4% and 96.4"2.6%,
225respectively (Fig. 3b). The linearised incidences of endo-
226carditis and reoperation were 0.48%ypt-yr and 0.3%ypt-yr,
227respectively.
2283.3.3. Major adverse valve-related events (MAVE)
229Forty-one patients (28.5%) experienced at least one
230important adverse valve-related event. In 14 patients, it
231resulted in death, which means that nearly two-thirds of
232the patients outlived the adverse event.
233One-, 5-, 10- and 15-year freedom from MAVE was 92.8"
2341.0%, 87.7"2.6%, 73.9"3.4% and 61.5"4.6%, respec-
235tively (Fig. 4). MAVE occurred at a linearised rate of 2.5%y
236pt-yr.
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100
101 Fig. 2. Freedom from (a) thromboembolism; and (b) major bleeding.
105
106
107 Fig. 3. Freedom from (a) endocarditis; and (b) reoperation.8
111
112 Fig. 4. Freedom from MAVE.3
237
4. Discussion
238 Our policy regarding AVR is to implant a mechanical
239 prosthesis in every ‘suitable’ patient until 70–72 years of
240
age. The ‘suitability’ is determined by a comprehensive
241conversation, firstly with the cardiologist and nurse who
242received the patient and secondly with the cardiac surgeon,
243with the patient.
244One particularity of this study is the long follow-up for
245this patient population, with a mean follow-up time of
24611.7"4.3 years and maximum of 19.1 years. At the com-
247pletion of this study more than half of the patients were
248alive, with ages ranging from 77 to 91 years (mean
24982.1"3.2), which probably would have placed some of
250them at risk of reoperation for structural valve deteriora-
251tion, if a bioprosthesis had been implanted.
252The overall 10- and 15-year actuarial survival of our
253patients was 67.7% and 58.5%, respectively, which is, in
254our opinion, remarkable for this specific patient population.
255It is important to emphasize that only half of the late
256deaths were from cardiac causes and only about one-fifth
257were valve-related, including three suddenyunexplained
258deaths, meaning that freedom from cardiac and valve-
259related mortality was significantly better than the overall
260survival observed. There was no significant difference when
261comparing the overall survival of this cohort of patients
262to the life expectancy of the general population above
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65 years of age (Institute of National Statistics; 16.9 vs.
264 17.9 years).
265 The fact that 18% of the patients suffered from at least
266 one episode of thromboembolism would appear to be a
267 high risk, but the linearised incidence (1.56%ypt-yr) is
268 perfectly admissible, notwithstanding the fact that throm-
269 boembolism also occurs with bioprostheses. Nevertheless,
270 it can be assumed that this percentage could be overesti-
271 mated because all the episodes of CVAyTIA were classified
272 as valve-related events and in most of them there was no
273 echocardiographic information regarding the valve status,
274 including the presence of thrombus. Furthermore, this
275 specific population is also susceptible to central neurolog-
276 ical events from other sources, such as aortic, carotid and
277 vertebral artery disease.
278 We observed a lower rate of major bleeding events
279 (0.84%ypt-yr), compared to others w13, 14x, but higher than
280 that reported in recent papers from Vicchio and colleagues 281
w15x who had a 5- and 10-year freedom from bleeding of
282 98.7% and 98.3%, respectively. We believe that this low
283 incidence of significant haemorrhage is partially due to
284 patient selection (good compliance to anticoagulation ther-
285 apy), to intensive nurse–patient education during hospital-
286 ization, explaining the necessity and risks of taking
287 anticoagulants, and, perhaps, to an aggressive follow-up by
288 the surgeons in the first months after discharge. In addition,
289 levels of anticoagulation were kept marginally lower than
290 those we use in younger patients. Naturally, this may have
291 had an impact in the incidence of thromboembolism.
292 As expected, prosthetic endocarditis was a fearful event,
293 with almost half of patients who experienced it dying as a
294 consequence. Only three patients who had endocarditis are
295 still alive and they were all treated conservatively.
296 Other reinterventions because of the aortic prosthesis
297 were rare, consistent with other results in the literature,
298 with 10- and 15-year freedom from reoperation of 96.9"
299 2.4% and 96.4"2.6%, respectively, which is certainly lower
300 than those usually described for bioprostheses after iden-
301 tical follow-up periods, even in this age group w4, 5x.
302 There are several limitations of this study. Firstly, it is
303 retrospective and the patients subject to selection bias,
304 although the decision to use a mechanical valve was col-
305 legial and not by individual surgeons, which assured consis-
306 tency. Because it represents a cross-sectional follow-up,
307 data on valve-related complications were not collected on
308 an ongoing basis. We tried to minimize this by a thorough
309 search for adverse events and review of all the clinical
310 files available looking for events that required hospitaliza-
311 tion. Secondly, a comparison with a similar group of elderly
312 patients undergoing bioprosthetic implantation would be of
313 extreme value. But our selection criteria for mechanical
314 valves precluded such comparison. Only a randomised study
315 could solve this issue.
316 At the end of the study, about two-thirds of our patients
317 were alive and free from MAVE. Hence, we consider implan-
318 tation of a mechanical prosthesis in elderly patients safe
319 and appropriate, but consider that the choice must be
320 tailored for each specific patient.
321
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Conference discussion
392 Dr. P. Simon (Al Kohober, Saudi Arabia): You describe in your paper the
393 outcomes of patients aged 65 years or older after aortic valve replacement
394 with a mechanical prosthesis, and you conclude from your findings that this
395 is a valid and safe practice. Your conclusion is well in line with several other
396 recent publications, which could not demonstrate either a clear survival
397 benefit, better freedom from adverse events, or quality of life advantages
398 with bioprosthesis over mechanical prosthesis in the older age group. So is
399 the pendulum swinging back after we have seen the indication for AVR using
400 bioprosthesis being expanded to younger patients because of low rates of
401 degeneration of the modern bioprosthesis, especially in older patients? So
402 how do we resolve this dilemma and choose the right type of prosthesis for
403 the individual patient? You stress in your manuscript very much the impor-
404 tance of careful patient selection, but you unfortunately do not tell us how
405 you do this. So this leads me to a few questions.
406 How many patients received a bioprosthesis in the same age group during
407 the same period and why is there no comparison? Secondly, what is the
408 current practice of you and your institution and what are the actual selection
409 criteria you used? Third, how do the current advances with transcatheter
410 valve replacement technologies becoming available, and especially the
411 concept of valve-in-a-valve replacement of a failing bioprosthesis, affect
412 your current practice or will it do so in the near future?
413 Dr. Coutinho: Regarding the first question, as I mentioned in the manu-
414 script, the policy of our department is to implant a mechanical prosthesis
415 in a suitable patient. The suitable patient goes until 70–72-year-old patient.
416 When we look at the results, two-thirds of the patients were alive at the
417 end of the study, and the mean age of the patients alive was 82.1 years,
418 which means that if we had implanted a bioprosthesis, probably this patient
419 would be at risk of reoperation. The mean overall survival was 13.6 years,
420 which I think is remarkable.
421 Regarding the selection, yes, the selection is by conversation with the
422 patient, beginning with the nurse and the cardiologist and, afterwards, the
423 surgeon; the performance status is analyzed; the capability of the patient
424
to manage the anticoagulation; the family support of the patient to be
425anticoagulated. There are several factors that we take into account when
426deciding to implant a mechanical prosthesis, but we are not saying that
427older patients should have a mechanical prosthesis.
428We decided to perform this study because this goes in the opposite direction
429of the recent tendency. The recent tendency is to use a bioprosthesis in
430increasingly younger patients. Well, with these results we can say that
431mechanical valve replacement is a safe and appropriate measure. There
432weren’t exclusion or inclusion criteria to this study. This is a retrospective
433analysis.
434Dr. Simon: So what is it you do now? Do you put mechanical valves in the
435patients 65 to 72, in all of them, or which ones?
436Dr. Coutinho: No, no. I have just answered that, if the patient is suitable
437for a mechanical prosthesis.
438Dr. J. Appoo (Calgary, Alberta, Canada): I have two questions. I think you
439had about 15% of patients at 10 years with a thromboembolic event but only
440three patients who had reoperation.
441Dr. Coutinho: Five patients were reoperated.
442Dr. Appoo: But none of them were reoperated for thromboembolism. So
443can you comment on that? If a patient has a thromboembolic event, do they
444usually require a reop or not? And secondly, at 10 years you had close to
44530% of patients with a major thromboembolic or a bleeding event, which
446is actually a significant morbidity, and I don’t think that can be
447underestimated.
448Dr. Coutinho: About the second question, yes, the gross analysis of 18% of
449the patients having a thromboembolic event seems inadmissible, but the
450linearized incidence was 1.56 per patient year.
451Dr. Appoo: But that is the whole point. 1.56 per patient year adds up to
45215% at 10 years, which is actually quite a high incidence. One-third of
453patients had a major complication at 10 years.
454Dr. Coutinho: One explanation for that is that we use a lower threshold
455for the level of anticoagulation. I don’t know if that could be a reason for
456having a thromboembolic event. But the linearized incidence is around the
457values cited by other works in other population groups. 8
